David A. Siegel Inozyme Pharma, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INZY
# of Institutions
92Shares Held
49MCall Options Held
1.6KPut Options Held
22K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.33MShares$23.9 Million0.08% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$20.2 Million25.25% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$19.2 Million1.91% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.68MShares$16.5 Million0.74% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.18MShares$14.3 Million0.39% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $180M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...